Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > NanoBio Launches Development Program for a Therapeutic Intranasal Vaccine for the Treatment of Hepatitis B

Abstract:
NanoBio® Corporation today announced an initiative to develop an intranasal vaccine for the treatment of hepatitis B (HBV). NanoBio and the University of Michigan's, Michigan Nanotechnology Institute for Medicine and Biological Sciences received funding through a Phase 1 Technology Transfer (STTR) award by the National Institutes of Health (NIH), to evaluate a potential therapeutic intranasal vaccine for the treatment of hepatitis B in patients. This development program represents the first of several potential therapeutic vaccines in a significant extension of NanoBio's vaccine platform.

NanoBio Launches Development Program for a Therapeutic Intranasal Vaccine for the Treatment of Hepatitis B

Ann Arbor, MI | Posted on April 22nd, 2010

Hepatitis B is an infection of the liver caused by the HBV virus. HBV is the most common cause of chronic viral liver disease worldwide. More than 370 million people are chronically infected with hepatitis B, leading to nearly one million deaths annually as a result of cirrhosis, and liver failure. HBV is transferred via bodily fluids and blood, and is commonly spread through sexual intercourse and intravenous drug use. Today, vaccinations are routinely given to infants to prevent infection contributing to lower rates of incidence in recent years. However, for patients previously infected, recurring infection is a concern that cannot be mitigated with existing vaccines.

"Currently available HBV vaccines are effective prophylactics, but lack therapeutic properties for those that are already infected," said James R. Baker, MD, CEO and founder of NanoBio. "This new intranasal vaccine would have great value as a treatment to reduce the risk of HBV associated liver diseases and deaths globally. The vaccine is also highly stable at room temperature enabling storage without refrigeration, a factor of great importance in the developing world."

Through this project, NanoBio and University of Michigan teams will demonstrate in animals the capabilities of a nanoemulsion-based HBV vaccine to safely induce immune responses in the presence of confounding factors such as kidney failure. This research is especially important as individuals with kidney function deficiencies are at high risk for complications of HBV infection when compared to normal individuals.

After successful completion of the preclinical studies funded by this STTR, NanoBio plans to conduct a FDA-approved Phase 1 clinical trial to evaluate safety, dose range, immunogenicity and preliminary efficacy against chronic HBV in humans with kidney failure.

####

About NanoBio Corporation
NanoBio Corporation is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company’s lead product candidates are treatments for herpes labialis (licensed to GSK in the U.S. and Canada), onychomycosis, acne, cystic fibrosis and a broad platform of intranasal vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.

About NanoBio’s Vaccine Platform
NanoBio’s nanoemulsion-based, intranasal vaccines have elicited robust immune responses in animals vaccinated against seasonal and pandemic influenza, hepatitis B, RSV, HIV, pneumococcal, anthrax, smallpox and other diseases. The company’s NanoStat™ adjuvant platform technology has demonstrated numerous potential advantages over traditional vaccines, including: the ability to generate robust mucosal, systemic and cellular immunity; antigen-sparing qualities; cross-protection against non-vaccinated strains; ability to adjuvant multiple antigen types without inducing inflammation; thermally stabilizing the vaccine; and removing the need for needles.

For more information, please click here

Contacts:
V.P. Business Development:
John Coffey (Ext. 107)

Copyright © NanoBio Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Iran to Hold 3rd Int'l Engineering Materials, Metallurgy Conference October 25th, 2014

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

SUNY Polytechnic Institute Invites the Public to Attend its Popular Statewide 'NANOvember' Series of Outreach and Educational Events October 23rd, 2014

Govt.-Legislation/Regulation/Funding/Policy

Novel Rocket Design Flight Tested: New Rocket Propellant and Motor Design Offers High Performance and Safety October 23rd, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

Brookhaven Lab Launches Computational Science Initiative:Leveraging computational science expertise and investments across the Laboratory to tackle "big data" challenges October 22nd, 2014

Bipolar Disorder Discovery at the Nano Level: Tiny structures found in brain synapses help scientists better understand disorder October 22nd, 2014

Academic/Education

SUNY Polytechnic Institute Invites the Public to Attend its Popular Statewide 'NANOvember' Series of Outreach and Educational Events October 23rd, 2014

First Canada Excellence Research Chair gets $10 million from the federal government for oilsands research at the University of Calgary: Federal government announces prestigious research chair to study improving oil production efficiency October 19th, 2014

Raytheon, UMass Lowell open on-campus research institute: Industry leader’s researchers to collaborate with faculty, students to move key technologies forward through first-of-its-kind partnership October 11th, 2014

SUNY Colleges of Nanoscale Science and Engineering and National Institute for Occupational Safety and Health Announce Expanded Partnership October 2nd, 2014

Nanomedicine

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014

Announcements

Iran to Hold 3rd Int'l Engineering Materials, Metallurgy Conference October 25th, 2014

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

Nanobiotechnology

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Nanoparticle technology triples the production of biogas October 23rd, 2014

Mechanism behind nature's sparkles revealed October 22nd, 2014

‘Designer’ nanodevice could improve treatment options for cancer sufferers October 22nd, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE